Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Senti Biosciences (SNTI) Research & Development (2021 - 2025)

Senti Biosciences has reported Research & Development over the past 5 years, most recently at $7.8 million for Q4 2025.

  • For Q4 2025, Research & Development changed 0.15% year-over-year to $7.8 million; the TTM value through Dec 2025 reached $37.6 million, up 9.4%, while the annual FY2025 figure was $37.6 million, 9.4% up from the prior year.
  • Research & Development for Q4 2025 was $7.8 million at Senti Biosciences, down from $10.5 million in the prior quarter.
  • Over five years, Research & Development peaked at $10.5 million in Q3 2025 and troughed at $5.2 million in Q2 2021.
  • A 5-year average of $8.0 million and a median of $7.8 million in 2024 define the central range for Research & Development.
  • Biggest five-year swings in Research & Development: soared 76.64% in 2022 and later fell 25.64% in 2023.
  • Year by year, Research & Development stood at $6.4 million in 2021, then rose by 9.8% to $7.0 million in 2022, then increased by 29.63% to $9.1 million in 2023, then decreased by 14.8% to $7.8 million in 2024, then dropped by 0.15% to $7.8 million in 2025.
  • Business Quant data shows Research & Development for SNTI at $7.8 million in Q4 2025, $10.5 million in Q3 2025, and $10.0 million in Q2 2025.